UAB "Novo Nordisk Pharma" Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data
| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2022 |
|---|
| 16,385,375 |
| 765,314 |
| 637,785 |
| 528,683 |
| 24,693 |
| 13.29 |
| 3.23 |
| 1,083,042 |
| 1,928,036 |
| 32,825 |
| 3,073,253 |
| 2023 |
|---|
| 21,820,183 |
| 935,284 |
| 912,567 |
| 752,671 |
| 32,262 |
| 12.00 |
| 3.45 |
| 1,835,713 |
| 4,375,007 |
| 35,460 |
| 6,332,559 |
| 2024 |
|---|
| 28,628,471 |
| 1,075,046 |
| 1,223,040 |
| 1,010,395 |
| 37,942 |
| 16.08 |
| 3.53 |
| 2,846,108 |
| 8,494,236 |
| 66,940 |
| 11,429,793 |
Register and
explore Okredo data| 2024 |
|---|
| 28,628,471 |
| 1,075,046 |
| 1,223,040 |
| 1,010,395 |
| 37,942 |
| 16.08 |
| 3.53 |
| 2,846,108 |
| 8,494,236 |
| 66,940 |
| 11,429,793 |
Register and
explore Okredo data2024
Turnover (€)
28,628,471 €
31 % *
Sales per employee (€)
1,075,046 €15 % *
Profit before tax (€)
1,223,040 €34 % *
Net Profit (€)
1,010,395 €34 % *
Profit per employee (€)
37,942 €18 % *
Total profitability (%)
16.08 %34.00 % *
Net profitability (%)
3.53 %2.32 % *
Equity (€)
2,846,108 €55 % *
Amounts Payable And Liabilities (€)
8,494,236 €
94 % *
Non-current Assets (€)
66,940 €89 % *
CurrentAssets (€)
11,429,793 €80 % *